Induction treatment with α‐interferon in multiple myeloma: An interim report from MGCS
Induction treatment with α‐interferon in multiple myeloma: An interim report from MGCS
复制标题
α-干扰素诱导治疗多发性骨髓瘤：MGCS 的中期报告
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
E. Ösby
中科院分区：
文献类型：
--
作者：
H. Mellstedt;A. Österborg;M. Björkholm;M. Björeman;G. Brenning;G. Gahrton;G. Grimfors;H. Gyllenhammar;R. Hast;B. Johansson;G. Juliusson;M. Järnmark;A. Killander;E. Kimby;R. Lerner;K. Merk;C. Paul;B. Simonsson;B. Smedmyr;A. Stalfelt;H. Strander;E. Svedmyr;A. Udén;B. Wadman;E. Ösby
1986年4月1日开始的一项随机研究，在未经治疗的II期和III期多发性骨髓瘤患者中比较了美法仑/泼尼松（M/P）治疗与MP +天然α-IFN治疗。到1989年3月，MP组有78例可评价，MP/IFN组有80例可评价。48%的MP患者获得应答，MP/IFN组为66%（p = 0.04）。II期患者对MP/IFN（76%）的反应优于单用MP（47%）（p = 0.02），而III期患者无统计学显著差异。90%的伊加骨髓瘤对MP/IFN有反应，52%对MP有反应（p = 0.02）。对于IgG和BJ骨髓瘤，MP/IFN的应答率均高于MP，但差异无统计学意义。观察期仍然很短。两个治疗组之间的总生存期没有差异。然而，在≤ 65岁的患者中，观察到接受IFN联合治疗的患者生存期延长的趋势（p = 0.12）。
A randomized study comparing melphalan/prednisone (M/P) therapy with MP + natural α‐IFN in untreated patients with multiple myeloma stages II and III started April 1, 1986. By March 1989, 78 patients were evaluable in the MP group and 80 in the MP/IFN group. 48% of the MP patients achieved a response and 66% in the MP/IFN group (p = 0.04). Stage II patients responded better to MP/IFN (76%) than MP alone (47%) (p = 0.02), while no statistically significant difference was noted for stage III patients. 90% of the IgA myelomas responded to MP/IFN and 52% to MP (p = 0.02). Both for IgG and BJ myelomas the response rates of MP/IFN were higher than of MP, although the differences were not statistically significant. The observation period is still short. There was no difference in total survival between the two treatment groups. However, in patients ≤ 65 years a tendency to a longer survival was seen for those receiving the IFN combination (p = 0.12).
先前未经治疗的多发性骨髓瘤患者的化疗：近期治疗结果的分析。
影响因子：
4
作者：
Sporn,JR;McIntyre,OR
通讯作者：
McIntyre,OR